(Z)-endoxifen
Metastatic Breast Cancer
Key Facts
About Atossa Therapeutics
Atossa Therapeutics is dedicated to transforming breast cancer care through patient-centric solutions and breakthrough science. Its primary focus is the development of (Z)-endoxifen, a novel SERM designed to be significantly more potent than existing options, with potential applications from prevention to metastatic treatment. As a publicly traded company, Atossa is advancing its clinical programs to target high-need breast cancer indications where current therapies are inadequate. The company's mission is to improve outcomes for the millions of women affected by breast cancer worldwide.
View full company profileAbout Atossa Therapeutics
Atossa Therapeutics is dedicated to transforming breast cancer care through patient-centric solutions and breakthrough science. Its primary focus is the development of (Z)-endoxifen, a novel SERM designed to be significantly more potent than existing options, with potential applications from prevention to metastatic treatment. As a publicly traded company, Atossa is advancing its clinical programs to target high-need breast cancer indications where current therapies are inadequate. The company's mission is to improve outcomes for the millions of women affected by breast cancer worldwide.
View full company profileTherapeutic Areas
Other Metastatic Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Lurbinectedin | Pharma Mar | Phase 2/3 |
| Alisertib | Puma Biotechnology | Phase 2 |
| Eftilagimod alfa (efti) | Immutep | Phase 2 |